CoChat

Risk stratification and medical therapy of pulmonary arterial hypertension

Open access

The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.

Abstract

Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the availability over the past 15 years of multiple drugs interfering with the endothelin, nitric oxide and prostacyclin pathways. The recent progress observed in medical therapy of PAH is not, therefore, related to the discovery of new pathways, but to the development of new strategies for combination therapy and on escalation of treatments based on systematic assessment of clinical response. The current treatment strategy is based on the severity of the newly diagnosed PAH patient as assessed by a multiparametric risk stratification approach. Clinical, exercise, right ventricular function and haemodynamic parameters are combined to define a low-, intermediate- or high-risk status according to the expected 1-year mortality. The current treatment algorithm provides the most appropriate initial strategy, including monotherapy, or double or triple combination therapy. Further treatment escalation is required in case low-risk status is not achieved in planned follow-up assessments. Lung transplantation may be required in most advanced cases on maximal medical therapy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1183/13993003.01889-2018

Cites

88 of 88 references verified0 citation errors · 0 not checkable

Statistics

Figures

FIGURE 1 Time-course of completed randomised controlled trials (RCTs) in pulmonary arterial hypertension (PAH) (n=41) according to treatment strategy. SSc: systemic sclerosis; IPAH: idiopathic PAH. Reproduced and modified from [70] with permission.
FIGURE 1 Time-course of completed randomised controlled trials (RCTs) in pulmonary arterial hypertension (PAH) (n=41) according to treatment strategy. SSc: systemic sclerosis; IPAH: idiopathic PAH. Reproduced and modified from [70] with permission.CC BY-NC · PubMed Central
FIGURE 2 Treatment algorithm. PAH: pulmonary arterial hypertension; IPAH: idiopathic PAH; HPAH: heritable PAH; DPAH: drug-induced PAH; CCB: calcium channel blocker; PCA: prostacyclin analogue; PH: pulmonary hypertension. a: 2015 ESC/ERS PH guidelines Table 16; b: 2015 ESC/ERS PH guidelines Table 17; c: 2015 ESC/ERS PH guidelines Table 18; d: 2015 ESC/ERS PH guidelines Table 13; e: 2015 ESC/ERS PH guidelines Table 19; f: 2015 ESC/ERS PH guidelines Table 20; g: 2015 ESC/ERS PH guidelines Table 14; h: 2015 ESC/ERS PH guidelines Table 21; i: maximal medical therapy is considered triple combination therapy including a s.c. or an i.v. PCA (i.v. preferred in high-risk status); j: 2015 ESC/ERS PH guidelines Table 22.
FIGURE 2 Treatment algorithm. PAH: pulmonary arterial hypertension; IPAH: idiopathic PAH; HPAH: heritable PAH; DPAH: drug-induced PAH; CCB: calcium channel blocker; PCA: prostacyclin analogue; PH: pulmonary hypertension. a: 2015 ESC/ERS PH guidelines Table 16; b: 2015 ESC/ERS PH guidelines Table 17; c: 2015 ESC/ERS PH guidelines Table 18; d: 2015 ESC/ERS PH guidelines Table 13; e: 2015 ESC/ERS PH guidelines Table 19; f: 2015 ESC/ERS PH guidelines Table 20; g: 2015 ESC/ERS PH guidelines Table 14; h: 2015 ESC/ERS PH guidelines Table 21; i: maximal medical therapy is considered triple combination therapy including a s.c. or an i.v. PCA (i.v. preferred in high-risk status); j: 2015 ESC/ERS PH guidelines Table 22.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 2

  1. Benza, 2018, Comparison of three assessment strategies as predictors of one-year survival in US pulmonary arterial hypertension (PAH) patients, Am J Respir Crit Care Med, 197, A7649
  2. Galiè, 2014, AMBITION: a randomised, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH), Eur Respir J, 44, 2916

Cited by

See all 897

Metadata

Authors
Galiè, N., Channick, R. N., Frantz, R. P., Grünig, E., Jing, Z. C., Moiseeva, O., Preston, I. R., Pulido, T., Safdar, Z., Tamura, Y., & McLaughlin, V. V.
Affiliations
  • University of Bologna (IT)
  • Harvard University (US)
  • Mayo Clinic (US)
  • University Hospital Heidelberg (DE)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • Tufts University (US)
  • Houston Methodist (US)
  • International University of Health and Welfare (JP)
  • University of Michigan (US)
Venue
European Respiratory Journal
Published
2019-01
Volume
53
Issue
1
Pages
1801889
ISSN
  • 0903-1936 (ISSN-L)
  • 1399-3003
OpenAlex
W2904385559
Cited by
819
References
88
Citations by year
2026: 32 · 2025: 46 · 2024: 101 · 2023: 108 · 2022: 174 · 2021: 169 · 2020: 128 · 2019: 58
FWCI
15.86
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • European Respiratory Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, other-oa)
Funders
Japan Society for the Promotion of Science (18K08183)
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
  • Health Sciences › Medicine › Genetics (clinical) › Vascular Anomalies and Treatments
  • Health Sciences › Medicine › Internal Medicine › Venous Thromboembolism Diagnosis and Management
Keywords
pulmonary arterial hypertension, risk stratification, medical therapy, combination therapy, treatment escalation, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, prostacyclin analogues, right ventricular function, exercise capacity, one-year mortality, lung transplantation, treatment algorithm
MeSH terms
Pulmonary Arterial Hypertension, Calcium Channel Blockers, Humans, Randomized Controlled Trials as Topic, Lung Transplantation, Practice Guidelines as Topic, Risk Assessment, Phosphodiesterase 5 Inhibitors, Endothelin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.